

July 11, 2019

Congress of the United States

Washington, D.C. 20515

The Honorable Robert E. Lighthizer
U.S. Trade Representative
600 17th Street, NW
Washington, D.C. 20508

Dear Ambassador Lighthizer:

We write to express our strong opposition to provisions that limit access to medicines in the revised NAFTA agreement, also known as United States-Mexico-Canada Agreement (USMCA). Without changes to the underlying trade agreement, patients will pay the high price of prescription drugs for longer and experience no relief from the financial burden often imposed on them and their families by unaffordable medication. We, thus, encourage you to amend the USMCA to increase competition and enhance patient access to more affordable prescription drugs, reflecting the balance achieved in the bipartisan May 10, 2007 agreement.

The USMCA would keep drug prices out of reach for patients by increasing and locking in 10 years of marketing exclusivity for brand biologics, expanding the scope of brand biologics eligible for protection, and making it easier for brand-name drug companies to extend their monopolies through additional patents, patent extensions, and other forms of patent “evergreening.” As recently noted by the Food and Drug Administration (FDA), brand biologics now represent 40 percent of all spending on prescription drugs and, from 2010 to 2015, comprised 70 percent of the growth in drug spending.¹ Brand biologics are “forecasted to be the fastest growing segment of drug spending in the coming years.”² Unfortunately, due to the aforementioned provisions, the USMCA would only exacerbate this trend. Unless the USMCA text is amended, it would limit Congress’ ability to adjust the biologics exclusivity period, instead locking the US into policies that keep cancer and other drug prices high while exporting this model to Mexico, which has no additional exclusivity period for biologics, and to Canada, which has an eight-year period.

In order to reduce the cost of prescription drugs for America’s patients, patient access to more affordable biosimilars must be enhanced and not delayed by additional monopoly protections for brand biologics. A recent Politico/Harvard poll found lowering prescription drug prices as one of the top overall priorities for the new Congress, with 89 percent of Republicans and 94 percent of Democrats saying it is “extremely important.”³ In contrast, however, polling from Morning Consult found 75 percent of the public is concerned that the USMCA will negatively impact drug prices and 81 percent believe our trade policies should increase – not decrease – access to affordable medicines.⁴

We, therefore, request revisions to the access to medicines provisions in the USMCA to make them consistent with the bipartisan May 10th standard. Improving patient access to more affordable medicines, in particular biosimilars, is essential to lowering prescription drug prices and a critical

¹ FDA Commissioner Scott Gottlieb, M.D., Remarks on the Release of the FDA’s Biosimilars Action Plan, July 28, 2018, available [online](#).

² Ibid.


³ Politico/Harvard, “Americans’ Health and Education Priorities for the New Congress in 2019,” January 2019, available [online](#).

⁴ Morning Consult, “Americans believe the new U.S.-Mexico-Canada trade agreement (USMCA) will keep drug prices high,” October 26-28, 2018, available [online](#).


component of the Administration's *Blueprint to Lower Drug Prices*. Otherwise, the USMCA only doubles down on the unsustainable trend of skyrocketing prescription drug costs by extending the monopoly protections awarded to brand-name drug companies.

We look forward to your reply and would be glad to work with you to improve the access to medicines provisions in the USMCA to benefit America's patients.

Sincerely,



Jan Schakowsky
Member of Congress



Susan A. Davis
Member of Congress



Lloyd Doggett
Member of Congress



Raja Krishnamoorthi
Member of Congress




Rosa L. DeLauro
Member of Congress




Angie Craig
Member of Congress




Andy Levin
Member of Congress



Susan Wild
Member of Congress



Jesus G. "Chuy" Garcia
Member of Congress



Suzanne Bonamici
Member of Congress



Salud O. Carbajal
Member of Congress



Matt Cartwright
Member of Congress




Andre Carson
Member of Congress



Ed Case
Member of Congress



Sean Casten
Member of Congress


Joaquin Castro
Member of Congress



Judy Chu
Member of Congress


David N. Cicilline
Member of Congress



Katherine M. Clark
Member of Congress


Yvette D. Clarke
Member of Congress


Steve Cohen
Member of Congress


Joe Courtney
Member of Congress


Elijah E. Cummings
Member of Congress


Danny K. Davis
Member of Congress


Peter A. DeFazio
Member of Congress


Diana DeGette
Member of Congress


Johanna Hayes
Member of Congress


Antonio Delgado
Member of Congress


Mark DeSaulnier
Member of Congress


Theodore E. Deutch
Member of Congress



Debbie Dingell
Member of Congress




Veronica Escobar
Member of Congress



Adriano Espaillat
Member of Congress




Lois Frankel
Member of Congress



John Garamendi
Member of Congress



Jared F. Golden
Member of Congress



Raul M. Grijalva
Member of Congress



Debra A. Haaland
Member of Congress




Brian Higgins
Member of Congress



Katie Hill
Member of Congress



Eleanor Holmes Norton
Member of Congress



Jared Huffman
Member of Congress



Pramila Jayapal
Member of Congress



Hakeem S. Jeffries
Member of Congress



Marcy Kaptur
Member of Congress



Joe Kennedy III
Member of Congress



Ro Khanna
Member of Congress



Daniel T. Kildee
Member of Congress



Ann Kirkpatrick
Member of Congress



Ann M. Kuster
Member of Congress



John B. Larson
Member of Congress




Brenda L. Lawrence
Member of Congress



Barbara Lee
Member of Congress



Ted W. Lieu
Member of Congress



Daniel Lipinski
Member of Congress




Alan Lowenthal
Member of Congress




Elaine G. Luria
Member of Congress




Tom Malinowski
Member of Congress



Carolyn B. Maloney
Member of Congress




James P. McGovern
Member of Congress




Grace Meng
Member of Congress





Joseph D. Morelle
Member of Congress


Jerrold Nadler
Member of Congress


Grace F. Napolitano
Member of Congress



Joe Neguse
Member of Congress


Donald Norcross
Member of Congress


Ilhan Omar
Member of Congress


Alexandria Ocasio-Cortez
Member of Congress



Chris Pappas
Member of Congress


Dean Phillips
Member of Congress


Chellie Pingree
Member of Congress


Mark Pocan
Member of Congress


Katie Porter
Member of Congress


Ayanna Pressley
Member of Congress


Jamie Raskin
Member of Congress


Max Rose
Member of Congress


Lucille Roybal-Allard
Member of Congress


Bobby L. Rush
Member of Congress



Tim Ryan
Member of Congress



John P. Sarbanes
Member of Congress



Mary Gay Scanlon
Member of Congress



Robert C. "Bobby" Scott
Member of Congress



Elissa Slotkin
Member of Congress



Darren Soto
Member of Congress



Mark Takano
Member of Congress



Dina Titus
Member of Congress



Rashida Tlaib
Member of Congress



Paul Tonko
Member of Congress




Norma J. Torres
Member of Congress



Lori Trahan
Member of Congress



Marc A. Veasey
Member of Congress




Nydia M. Velázquez
Member of Congress



Peter J. Visclosky
Member of Congress



Debbie Wasserman Schultz
Member of Congress



Peter Welch
Member of Congress



John A. Yarmuth
Member of Congress

Kathy Castor

Kathy Castor
Member of Congress

Emanuel Cleaver

Emanuel Cleaver
Member of Congress

Alice L. Hastings

Alice L. Hastings
Member of Congress

Stephen Lynch

Stephen Lynch
Member of Congress

Betty McCollum

Betty McCollum
Member of Congress

Frederica S. Wilson

Frederica S. Wilson
Member of Congress

John Lewis

John Lewis
Member of Congress

David Trone

David Trone
Member of Congress